Risk Stratified Sequential Treatment for CD20-positive PTLD
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This phase-II trial will investigate the efficacy, safety and the tolerability of a
sequential therapy consisting of 4 courses of single agent rituximab followed by 4 courses of
R-CHOP chemotherapy in patients with CD20+ posttransplant lymphoproliferative disorders
(PTLD). However, responders to rituximab achieving a CR after the first 4 applications of
rituximab will go on with rituximab monotherapy and will not receive chemotherapy.